Neoadjuvant versus PeriOp Immunotherapy in NSCLC | Oncology Brothers |  

In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss:
- Keynote 671 - perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data
- ALINA - resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS
- TropionLung 01 - Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel
#ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers
Website: www.oncbrothers...
Twitter: / oncbrothers
Contact us at info@oncbrothers.com